Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
08/2003
08/20/2003CN1437591A Compounds and methods for modulation of estrogen receptors
08/20/2003CN1437588A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type l
08/20/2003CN1437584A Tricyclic protein kinase inhibitors
08/19/2003US6608203 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
08/19/2003US6608197 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
08/19/2003US6608105 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation
08/19/2003US6608068 Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents
08/19/2003US6608030 Inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence
08/19/2003US6607757 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism
08/14/2003WO2003067221A2 Compositions and methods for restoring immune responsiveness in patients with immunological defects
08/14/2003WO2003066859A2 Amino acid sequences capable of facilitating penetration across a biological barrier
08/14/2003WO2003066813A2 MINRs AS MODIFIERS OF INSULIN RECEPTOR SIGNALING AND METHODS OF USE
08/14/2003WO2003066672A1 Peptides
08/14/2003WO2003066656A1 Crystalline complexes of fluticasone 2-furoate
08/14/2003WO2003066655A1 Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
08/14/2003WO2003066654A1 Process for the production of 6.alpha.,9.alpha-difluoro-17.alpha.-(1-oxopropoxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17.beta.-carbothioic acid
08/14/2003WO2003066608A1 Catechol bioisosteres
08/14/2003WO2003066585A2 Polymer-based compositions for sustained release
08/14/2003WO2003066077A2 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
08/14/2003WO2003066063A1 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist
08/14/2003WO2003066024A1 Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions
08/14/2003WO2003065999A2 Proliferated cell lines and uses thereof
08/14/2003WO2003065987A2 Granzyme b inhibitors
08/14/2003WO2003065983A2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
08/14/2003WO2003037335A8 5-heteroatom-substituted pyrazoles
08/14/2003WO2003031568A8 Intracellular signaling molecules
08/14/2003WO2002064083A3 Synthesis of 3-amino-thalidomide and its enantiomers
08/14/2003WO2002015933A3 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
08/14/2003WO2001092527A3 Regulators of apoptosis
08/14/2003WO2001092292A3 Ghrelin analogs
08/14/2003WO2001090148A3 Neurotransmitter transporters
08/14/2003US20030153627 Compounds for blocking androgen receptors
08/14/2003US20030153625 Suppressing bone disordes such as decalcification or fractures in humans having prostate gland cancers by administering antiestrogen selected from triphenylethylene or toremifene; hormone inhibitors
08/14/2003US20030153568 Serine/threonine and tyrosine kinases inhibitors
08/14/2003US20030153563 CRF receptor antagonists and methods relating thereto
08/14/2003US20030153542 Novel anti-inflammatory androstane derivative compositions
08/14/2003US20030153540 For improving health in a woman having elevated sex hormone binding globulin levels, or who is receiving oral estrogen supplementation
08/14/2003US20030153523 Screening library of test compounds, each of which is attached to a solid support, with a dye-labeled RNA molecule to form a dye-labeled target RNA:support-attached test compound complex
08/14/2003US20030153504 Antiinflammatory agents selects from a group of tetrapeptides, hexapeptides, octapeptides, oligopeptides, polypeptides
08/14/2003US20030153490 Insulin conjugates and methods of use thereof
08/14/2003US20030152615 Enhanced drug delivery in transdermal systems
08/14/2003US20030152614 Enhanced drug delivery in transdermal systems
08/14/2003US20030152613 Steroid on carrier containing pressure sensitive adhesive
08/14/2003CA2476214A1 Proliferated cell lines and uses thereof
08/14/2003CA2474917A1 Granzyme b inhibitors
08/14/2003CA2474283A1 Amino acid sequences capable of facilitating penetration across a biological barrier
08/14/2003CA2474186A1 Compositions and methods for restoring immune responsiveness in patients with immunological defects
08/14/2003CA2474168A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
08/14/2003CA2473753A1 Process for the production of 6.alpha.,9.alpha-difluoro-17.alpha.-(1-oxopropoxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17.beta.-carbothioic acid
08/14/2003CA2473499A1 Minrs as modifiers of insulin receptor signaling and methods of use
08/13/2003EP1334972A1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH)
08/13/2003EP1334724A1 Compositions for external preparations
08/13/2003EP1334367A2 A method of determining the initial dose of vitamin d compounds
08/13/2003EP1334106A2 Novel imidazole derivatives, production method thereof and use thereof
08/13/2003EP1333853A1 Growth factor complex
08/13/2003EP1333842A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
08/13/2003EP1333841A2 M. tuberculosis chaperonin 10 and uses thereof
08/13/2003EP1333840A2 M. tuberculosis chaperonin 60.1 and uses thereof
08/13/2003EP1333827A2 Estrogen receptor modulators
08/13/2003EP1333821A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists
08/13/2003EP1333719A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
08/13/2003EP0614374B1 MURINE MONOCLONAL ANTIBODY (5c8) RECOGNIZES A HUMAN GLYCOPROTEIN ON THE SURFACE OF T-LYMPHOCYTES
08/13/2003CN1436235A Anti-angiogenic polypeptides
08/13/2003CN1436081A Starter kit for low dose oral contraceptives
08/13/2003CN1435215A Zaizao Pill for treating woman diseases
08/13/2003CN1117732C Noval Dihydronaphthalene compound and process for producing same
08/13/2003CN1117567C Paroxetine controlled release compositions
08/12/2003US6605632 Affinity for melatonin receptors
08/12/2003US6605592 Protein HOFNF53
08/12/2003CA2418712A1 Non-peptide gnrh agents, pharmaceutical compositions, and methods for their use
08/08/2003CA2417305A1 Method of affecting sleep & sleep-related behaviours
08/07/2003WO2003064629A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003WO2003064443A2 New corticosteroids
08/07/2003WO2003064429A1 Thienopyrimidines, process for preparing the same and use thereof
08/07/2003WO2003064419A1 Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
08/07/2003WO2003064369A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003WO2003063893A2 Fgfr agonists
08/07/2003WO2003063892A1 Use of apelin
08/07/2003WO2003063880A1 Disruption of islet amyloid by polycyclic compounds
08/07/2003WO2003063859A1 Suppression of cartilage degradation via the estrogen receptor
08/07/2003WO2003063850A1 Medicinal compositions containing vitamin k’s as nerve growth factor potentiator and utilization thereof
08/07/2003WO2003063846A2 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
08/07/2003WO2003063800A2 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/07/2003WO2003046556A3 Globin biopolymer markers indicative of insulin resistance
08/07/2003WO2003030616A3 21132, a human g-protein coupled receptor family member and uses therefor
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003US20030149296 Such as 3-(4-salicyloylamino)phenoxypropionic acid; noncovalent drug delivery
08/07/2003US20030149268 Administering non-steroidal 9-pyrido(3,2-g)quinoline compounds to the mammal for affecting androgen receptor activity
08/07/2003US20030149113 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
08/07/2003US20030149104 Tri-substituted phenyl derivatives and analogues
08/07/2003US20030149091 For therapy of inflammatory bowel disease, ulcerative colitis, pyoderma gangrenosum, Crohn's disease, irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder
08/07/2003US20030149079 Novel benzofuran derivatives
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149026 For therapy of arthritis, fever, common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, etc.
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030148948 Super-active porcine growth hormone releasing hormone analog
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148946 Method and compositions for preventing hormone induced adverse effects
08/07/2003US20030148394 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
08/07/2003CA2474845A1 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
1 ... 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 ... 290